SARS-CoV-2 variants: A case for expanding mRNA vaccine production globally
Biopharma companies of West approach big Indian CROs & CDMOs for multi-dimensional solutions
How Syngene International’s CFO is balancing current risks with future viability
Artificial Intelligence – a game changer in revolutionizing drug discovery
CEO Spotlight: Jonathan Hunt, MD and CEO, Syngene International Limited
Syngene COO On Delivering Cost Gains For mRNA Products
How CDMOs are Adapting to New mRNA Tech Demands
Why Indian Pharma Must Evolve As Value Creator
CRAMS underpinned by strong technical expertise
Orphan drug development remains a specialised segment with limited players
